TG Therapeutics Lifts 2026 Revenue Outlook to ~$950M on Robust BRIUMVI Momentum
TGTX has more than doubled off its 52-week low of $25.28.
Summary
TG Therapeutics posted Q2 2026 BRIUMVI U.S. revenue of $228M (+64% YoY), raised full-year total revenue guidance to ~$950M, and advanced its pipeline with new Phase 2 trials in myasthenia gravis and schizophrenia.
Key Events · Earnings and Guidance · TGTX
-
BRIUMVI Q2 Revenue Surges 64%
U.S. net product revenue reached $227.7M in Q2 2026, up from $138.8M in Q2 2025, driving total global revenue to $240.3M.
-
Full-Year Guidance Raised Significantly
The 2026 total global revenue target has been raised to ~$950M, with BRIUMVI U.S. net product revenue now seen at $890–$905M, implying a ~$1B annualized run rate by year-end.
-
Pipeline Expands into New Indications
Phase 2 trials for BRIUMVI in myasthenia gravis and schizophrenia have been initiated; subcutaneous BRIUMVI Phase 3 data is expected by year-end 2026 or early 2027.
-
Strong Balance Sheet Supports Growth
Cash and investments of $612.3M as of June 30, 2026, combined with projected BRIUMVI revenues, are expected to fund operations under the current plan.
Analysis · TGTX · Life Sciences
Another beat-and-raise quarter underscores the commercial strength of BRIUMVI, with U.S. net product revenue climbing 64% year-over-year to $228M in Q2. The full-year total global revenue guide now sits at ~$950M, up from the prior $875–$900M range, pointing to a ~$1B annualized U.S. run rate by year-end. Profitability held firm at $7.8M in net income, and a $612M cash balance funds an expanding pipeline that now includes Phase 2 trials in myasthenia gravis and schizophrenia. Subcutaneous BRIUMVI Phase 3 data, expected around year-end, represents a key catalyst that could meaningfully broaden the addressable market. The raised guidance and pipeline progress together reinforce the commercial momentum and long-term growth narrative.
At the time of this filing, TGTX was trading at $50.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8B. The 52-week trading range was $25.28 to $59.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.